Safety and Oncologic Outcomes of Magnetic Resonance Imaging-Guided Cryoablation of Renal Cell Carcinoma: A 10-Year Single-Center Experience.
Journal
Investigative radiology
ISSN: 1536-0210
Titre abrégé: Invest Radiol
Pays: United States
ID NLM: 0045377
Informations de publication
Date de publication:
01 03 2021
01 03 2021
Historique:
pubmed:
9
9
2020
medline:
16
10
2021
entrez:
8
9
2020
Statut:
ppublish
Résumé
Magnetic resonance imaging guidance has been sporadically reported for renal tumor cryoablation (CA); therefore, clinical experience with this modality is still limited.The aim of this study is to retrospectively analyze our 10-year experience with renal tumor CA performed on a 1.5 T magnetic resonance imaging unit with the intent of reporting procedural safety and oncologic outcomes. We included 143 patients (102 men; 41 women; median age, 73 years; range, 34-91 years) with 149 tumors (median size, 2.6 cm; range, 0.6-6.0 cm), treated between 2009 and 2019. Patient, tumor, procedure, and follow-up data were collected and analyzed. The Kaplan-Meier method was used to estimate local recurrence-free (LRFS), metastasis-free (MFS), disease-free (DFS), cancer-specific, and overall (OS) survival. Univariate and multivariate models were used to identify factors associated with complications, LRFS, MFS, DFS, and OS. The overall complication rate was 10.7% (16/149 tumors), with 1 major (1/149 [0.7%]; 95% confidence interval, 0.0%-3.7%) hemorrhagic complication. Other minor complications (15/149 [10.1%]; 95% confidence interval, 0.6%-16.1%) did not include any cases of injury to nearby organs. There were no factors associated with complications.Five-year estimates of LRFS (primary/secondary), MFS, DFS, cancer-specific survival, and OS were 82.8%/91.5%, 91.1%, 75.1%, 98.2%, and 89.6%, respectively. Increasing tumor size (hazard radio [HR], 1.8; P = 0.02) and intraparenchymal tumor location (HR, 5.6; P < 0.01) were associated with lower LRFS; increasing patient's age (HR, 0.5; P = 0.01), high tumor grade (HR, 23.3; P < 0.01) and non-clear-cell/nonpapillary histology (HR, 20.1; P < 0.01) with metastatic disease; and high tumor grade (HR, 3.2; P = 0.04) with lower DFS. Magnetic resonance imaging-guided CA of renal tumors is associated with acceptable morbidity and high survival estimates at 5-year follow-up. Given the absence of complications resulting from injuries to nearby organs, further studies are required to evaluate whether the potential reduced incidence of these adverse events justifies large-scale implementation of this interventional modality.
Identifiants
pubmed: 32897930
pii: 00004424-202103000-00004
doi: 10.1097/RLI.0000000000000719
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
153-162Informations de copyright
Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.
Déclaration de conflit d'intérêts
Conflicts of interest and source of funding: Drs Gangi and Garnon are advisors to BTG.
Références
Xing M, Kokabi N, Zhang D, et al. Comparative effectiveness of thermal ablation, surgical resection, and active surveillance for T1a renal cell carcinoma: a surveillance, epidemiology, and end results (SEER)-Medicare-linked population study. Radiology . 2018;288:81–90.
Rosenberg MD, Kim CY, Tsivian M, et al. Percutaneous cryoablation of renal lesions with radiographic ice ball involvement of the renal sinus: analysis of hemorrhagic and collecting system complications. AJR Am J Roentgenol . 2011;196:935–939.
Allaf ME, Varkarakis IM, Bhayani SB, et al. Pain control requirements for percutaneous ablation of renal tumors: cryoablation versus radiofrequency ablation–initial observations. Radiology . 2005;237:366–370.
Cazzato RL, Garnon J, Ramamurthy N, et al. Percutaneous image-guided cryoablation: current applications and results in the oncologic field. Med Oncol . 2016;33:140.
Yamanaka T, Yamakado K, Yamada T, et al. CT-guided percutaneous cryoablation in renal cell carcinoma: factors affecting local tumor control. J Vasc Interv Radiol . 2015;26:1147–1153.
McEachen JC, Leng S, Atwell TD, et al. Percutaneous renal tumor ablation: radiation exposure during cryoablation and radiofrequency ablation. Cardiovasc Intervent Radiol . 2016;39:233–238.
Ahrar K, Ahrar JU, Javadi S, et al. Real-time magnetic resonance imaging-guided cryoablation of small renal tumors at 1.5 T. Invest Radiol . 2013;48:437–444.
Cazzato RL, Garnon J, Shaygi B, et al. How to perform a routine cryoablation under MRI guidance. Top Magn Reson Imaging . 2018;27:33–38.
Miki K, Shimomura T, Yamada H, et al. Percutaneous cryoablation of renal cell carcinoma guided by horizontal open magnetic resonance imaging. Int J Urol . 2006;13:880–884.
Caviezel A, Terraz S, Schmidlin F, et al. Percutaneous cryoablation of small kidney tumours under magnetic resonance imaging guidance: medium-term follow-up. Scand J Urol Nephrol . 2008;42:412–416.
Silverman SG, Tuncali K, vanSonnenberg E, et al. Renal tumors: MR imaging-guided percutaneous cryotherapy—initial experience in 23 patients. Radiology . 2005;236:716–724.
van Oostenbrugge TJ, Langenhuijsen JF, Overduin CG, et al. Percutaneous MR imaging-guided cryoablation of small renal masses in a 3-T closed-bore MR imaging environment: initial experience. J Vasc Interv Radiol . 2017;28:1098–1107.e1.
Buy X, Lang H, Garnon J, et al. Percutaneous renal cryoablation: prospective experience treating 120 consecutive tumors. AJR Am J Roentgenol . 2013;201:1353–1361.
Cardella JF, Kundu S, Miller DL, et al. Society of interventional radiology clinical practice guidelines. J Vasc Interv Radiol . 2009;20(suppl 7):S189–S191.
Kutikov A, Uzzo RG. The R.E.N.A.L. nephrometry score: a comprehensive standardized system for quantitating renal tumor size, location and depth. J Urol . 2009;182:844–8531.
Clavien PA, Barkun J, de Oliveira ML, et al. The Clavien-Dindo classification of surgical complications: five-year experience. Ann Surg . 2009;250:187–196.
Garnon J, Van Strijen MJ, Nielsen TK, et al. Safety of percutaneous renal cryoablation: an international multicentre experience from the EuRECA retrospective percutaneous database. Eur Radiol . 2019;29:6293–6299.
Kakarala B, Frangakis CE, Rodriguez R, et al. Hemorrhagic complications of percutaneous cryoablation for renal tumors: results from a 7-year prospective study. Cardiovasc Intervent Radiol . 2016;39:1604–1610.
Blute ML Jr., Okhunov Z, Moreira DM, et al. Image-guided percutaneous renal cryoablation: preoperative risk factors for recurrence and complications. BJU Int . 2013;111(4 pt B):E181–E185.
Breen DJ, King AJ, Patel N, et al. Image-guided cryoablation for sporadic renal cell carcinoma: three- and 5-year outcomes in 220 patients with biopsy-proven renal cell carcinoma. Radiology . 2018;289:554–561.
Okhunov Z, Moreira DM, Del Junco M, et al. Predictors of complications after percutaneous image-guided renal cryoablation for T1a renal cortical neoplasms. J Endourol . 2017;31:7–13.
Kim EH, Tanagho YS, Bhayani SB, et al. Percutaneous cryoablation of renal masses: Washington University experience of treating 129 tumours. BJU Int . 2013;111:872–879.
Kim EH, Tanagho YS, Saad NE, et al. Comparison of laparoscopic and percutaneous cryoablation for treatment of renal masses. Urology . 2014;83:1081–1087.
Pickersgill NA, Vetter JM, Kim EH, et al. Ten-year experience with percutaneous cryoablation of renal tumors: tumor size predicts disease progression [published online ahead of print June 22, 2020]. J Endourol . doi:10.1089/end.2019.0882.
doi: 10.1089/end.2019.0882
Tracy CR, Kogan P, Gupta A, et al. Radiation exposure during percutaneous ablation of small renal masses: a multi-institutional multimodality analysis. J Endourol . 2015;29:1314–1320.
Zhou W, Uppot RN, Feldman AS, et al. Percutaneous image-guided thermal ablation for multifocal renal cell carcinoma: 10-year experience at a single center. AJR Am J Roentgenol . 2017;209:733–739.
Kim DK, Won JY, Park SY. Percutaneous cryoablation for renal cell carcinoma using ultrasound-guided targeting and computed tomography-guided ice-ball monitoring: radiation dose and short-term outcomes. Acta Radiol . 2019;60:798–804.
Attenberger UI, Biber S, Wichtmann BD. Technological advances of magnetic resonance imaging in today's health care environment [published online ahead of print June 1, 2020]. Invest Radiol . doi:10.1097/RLI.0000000000000678.
doi: 10.1097/RLI.0000000000000678
Zargar H, Samarasekera D, Khalifeh A, et al. Laparoscopic vs percutaneous cryoablation for the small renal mass: 15-year experience at a single center. Urology . 2015;85:850–855.
Goyal J, Verma P, Sidana A, et al. Single-center comparative oncologic outcomes of surgical and percutaneous cryoablation for treatment of renal tumors. J Endourol . 2012;26:1413–1419.
Morkos J, Porosnicu Rodriguez KA, Zhou A, et al. Percutaneous cryoablation for stage 1 renal cell carcinoma: outcomes from a 10-year prospective study and comparison with matched cohorts from the National Cancer Database. Radiology . 2020;296:452–459.
Mouli SK, McDevitt JL, Su YK, et al. Analysis of the RENAL and mRENAL scores and the relative importance of their components in the prediction of complications and local progression after percutaneous renal cryoablation. J Vasc Interv Radiol . 2017;28:860–867.
Murray CA, Welch BT, Schmit GD, et al. Safety and efficacy of percutaneous image-guided cryoablation of completely endophytic renal masses. Urology . 2019;133:151–156.
Nonboe LL, Nielsen TK, Høyer S, et al. Arterial clamping increases central renal cryoablation efficacy: an animal study. Technol Cancer Res Treat . 2017;16:414–420.
Adams LC, Ralla B, Jurmeister P, et al. Native T1 mapping as an in vivo biomarker for the identification of higher-grade renal cell carcinoma: correlation with histopathological findings. Invest Radiol . 2019;54:118–128.
Beksac AT, Rivera-Sanfeliz G, Dufour CA, et al. Impact of tumor histology and grade on treatment success of percutaneous renal cryoablation. World J Urol . 2017;35:633–640.
Dreyfuss LD, Wells SA, Best SL, et al. Development of a risk-stratified approach for follow-up imaging after percutaneous thermal ablation of sporadic stage one renal cell carcinoma. Urology . 2019;134:148–153.
Ke ZB, Chen SH, Chen YH, et al. Risk factors for brain metastases in patients with renal cell carcinoma. Biomed Res Int . 2020;2020:6836234.
Chandrasekar T, Klaassen Z, Goldberg H, et al. Metastatic renal cell carcinoma: Patterns and predictors of metastases-A contemporary population-based series. Urol Oncol . 2017;35:661.e7–661.e14.